Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Snippets - A Small piece of News or Article

Golcadomide in B-Cell Lymphoma

Snippets - A Small piece of News or Article

Harmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma

Explore More...
ALLO-647 for Lymphodepletion

ALLO-647 Integration in Lymphodepletion: Paving the Way for Enduring Responses and Safe CAR T cell Therapy Advancements

Golcadomide-Rituximab Combo in DLBCL Patient

Golcadomide and Rituximab Combo Unveils Promising Efficacy in Heavily Pretreated Relapsed/Refractory DLBCL

ZYNLONTA-Rituximab Combo in Follicular Lymphoma

Pioneering Progress: ZYNLONTA and Rituximab Combo Delivers Striking 96% Overall Response in Relapsed Follicular Lymphoma

Breaking Ground: Ibrutinib and Venetoclax Synergy Delivers Significant Progression-Free Survival Boost in Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 trial of Bgb-16673

BGB-16673 Breakthrough: A Tolerable Triumph in Rapid Clinical Responses for Relapsed/Refractory B-Cell Malignancies

Phase 1b MonumenTAL-2 Study Result

TALVEY’s Versatility Shines: Key Insights from MonumenTAL-2 Study Illuminate Effective Strategies in Relapsed/Refractory Multiple Myeloma

Breakthrough Success: AUGMENT-101 Trial Hits Primary Endpoint with Consistent CR/CRh Rates Across Adult and Pediatric KMT2Ar AML and ALL Cohorts

Phase 3 Results Support D-VRd

DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for Newly Diagnosed Multiple Myeloma Eligible for Transplantation

Phase 3 CARTITUDE-4 Study

Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma

Phase 2 CARTITUDE-2 Trial of Ciltacabtagene Autoleucel

Cilta-Cel’s Prolonged Impact: Deep Responses and Safety Insights from Earlier Lines of Therapy in Multiple Myeloma

Phase 2 ELM-2 Study in Patients with DLBCL

Odronextamab Trial: Striking Response Rates and Enduring Outcomes in High-Risk R/R DLBCL Subgroups

Phase 1/2 BRUIN Study of Pirtobrutinib

Pirtobrutinib Monotherapy: A Promising Beacon of Efficacy and Safety in Relapsed/Refractory Follicular Lymphoma Patients

Phase I/II EPCORE NHL-1 Trial Update

EPCORE NHL-1 Trial Reveals Promising Response Rates for Investigational Follicular Lymphoma Therapy: A Game-Changing Alternative in Focus

Analysis of the Phase 2 PILOT Study

Liso-cel (lisocabtagene maraleucel) Shines in Second-Line, Yielding Long-Lasting Complete Responses for Non-Transplant Eligible LBCL Patients

Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment

Highlight of Liso-cel

Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Manageable Safety as a Second-Line Treatment for Relapsed Follicular Lymphoma

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader